Human FLT1 recombinant protein

Description of Human FLT1 recombinant protein

General information on Human FLT1 recombinant protein

Human FLT1 Recombinant Protein: Structure and Activity

Human Fms-like tyrosine kinase 1 (FLT1) is a type I membrane receptor belonging to the vascular endothelial growth factor receptor (VEGFR) family. It is composed of an extracellular domain, a single transmembrane domain, and an intracellular domain. The extracellular domain of FLT1 binds to VEGF-A, VEGF-C, and VEGF-D, while the intracellular domain has tyrosine kinase activity. FLT1 is involved in the regulation of angiogenesis, vascular permeability, and cell proliferation.

FLT1 as an Antibody-Drug Target

FLT1 is an attractive target for antibody-drug conjugates (ADCs) due to its role in tumor growth and angiogenesis. ADCs are composed of an antibody linked to a cytotoxic drug. The antibody binds to the FLT1 receptor and the drug is internalized, leading to cell death. FLT1-targeted ADCs have been used in clinical trials for various types of cancer, including ovarian, gastric, and colorectal cancers.

Icrucumab Biosimilar - Anti-FLT1, VEGFR-1 mAb binds to Human FLT1 recombinant protein in indirect ELISA Assay

Immobilized Human FLT1 recombinant protein (cat. No.PX-P6096) at 0.5µg/mL (100µL/well) can bind to Icrucumab Biosimilar - Anti-FLT1, VEGFR-1 mAb (cat. No.PX-TA1257) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450